ECTRIMS: Joining Novartis and Roche in fight for MS shares, Merck KGaA touts Mavenclad data

13th September 2019 Uncategorised 0

Roche’s Ocrevus and Novartis’ Mayzent may have grabbed headlines as favorites in multiple sclerosis treatment, but Merck KGaA is also stacking up data showing its Mavenclad helped keep disability at bay in 75% of patients five years after treatment.

More: ECTRIMS: Joining Novartis and Roche in fight for MS shares, Merck KGaA touts Mavenclad data
Source: fierce